For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Identity context
Notice of Concern: McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, and Harding JW (2013) Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents, <i>J Pharmacol Exp Ther</i>, 344: 141-154; DOI: https://doi.org/10.1124/jpet.112.199497.
Rat cognition models and cells
Reported findings. Expression of concern is linked to experimental Dihexa study; findings withheld.
Nonresponse. Human efficacy not established by this source.
Harms. Disputed study is not ordinary verified benefit evidence; concern is not retraction.
Limits. Review original concern before interpreting disputed study.
Preparation: Dihexa research preparation Route: oral/IP/ICV in rats
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Lab or animal research
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.
Male APP/PS1 mice treated from ages6-9months for three months; maze figures12/group, tissue figures6/group.
Reported findings. Reported shorter maze escape latency, more platform crossings and improved neuronal, synaptophysin and inflammatory markers.
Nonresponse. Swimming speed unchanged.
Harms. Dedicated toxicity or adverse-event assessment unreported; safety not established.
Limits. Contradictory route wording prevents assigning oral or intraperitoneal efficacy alone. Wortmannin reversed tissue-marker effects; inhibitor-only control absent. Pathway involvement does not establish HGF/c-Met mediation. Study cites older PMID23055539, which has expression of concern34551989. That older record remains withheld; no linked notice found for this later study is not comprehensive lifecycle clearance. Retraction40312093 targets separate2014paper25187433, not this2021paper; lifecycle status is not transferred between papers.
Preparation: MedChemExpress Dihexa, N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide; lot, purity and independent identity verification unreported. Route: Unresolved: methods describe intragastric administration then intraperitoneal Dihexa; results say intragastric and discussion describes injections.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.
Lab or animal research
Effects of an AngiotensinIV Analog on3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats
40 male Wistar rats randomized tovehicle,3NP,and3NP+Dihexa; five-week toxin-inducedHD-like model.
Reported findings. No protective benefit was reported in this model.
Nonresponse. Dihexa did not protect against toxin-associated weight-gain,spatial-learning/memory or motor deficits.
Harms. Dedicated compound harms assessment unverified in accessible abstract; toxin-related deficits cannot be labeled Dihexa toxicity.
Limits. A toxin rat model is not genetically confirmed humanHD or a human efficacy test. This is an independent later experiment with nulls, not a lifecycle correction or causal rebuttal of every positive Dihexa paper. Fresh EuropePMC metadata has no linked correction/retraction; original publisher preview does not show notice, comprehensive clearance not asserted. Original publisher abstract/date accessed via web tool; guarded raw publisher fetch403 was stopped. Full methods,funding/COI and peptide delivery route unavailable.
Preparation: PNB0408 explicitly identified in original abstract as Dihexa/N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; study preparation identity claim, not batch validation. Route: Dihexa route not specified in reviewed primary abstract. Systemic route wording describes neurotoxin, not automatically Dihexa.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.